Actively Recruiting
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Led by Ruijin Hospital · Updated on 2025-06-18
55
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
R
Ruijin Hospital
Lead Sponsor
S
Shanghai Jiao Tong University School of Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
CONDITIONS
Official Title
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to sign informed consent and follow study procedures
- Age 18 to 75 years at the time of consent, any gender
- Histopathologically confirmed unresectable locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction
- No prior systemic therapy for the cancer
- Confirmed Claudin 18.2-positive disease
- Eastern Cooperative Oncology Group performance status of 0 or 1
You will not qualify if you...
- HER2-positive disease defined by specific immunohistochemistry or in situ hybridization criteria
- Currently participating in another interventional clinical study, except survival follow-up
- History of treatment with topoisomerase inhibitor-based antibody-drug conjugates
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
R
Ruijin Hospital, Shanghai Jiao Tong University School of Medic
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here